Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int Immunopharmacol ; 31: 239-47, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26773771

RESUMO

meso-Dihydroguaiaretic acid (MDGA), which is a dibenzylbutane lignin isolated from the ethyl acetate fraction of Saururus chinensis, has various biological activities, including anti-oxidative, anti-inflammatory, anti-bacterial, and neuroprotective effects. However, no report has examined the potential anti-asthmatic activity of MDGA. In this study, we evaluated the protective effects of MDGA on asthmatic responses, particularly airway inflammation and mucus hypersecretion in an ovalbumin (OVA)-induced murine model of asthma. Intragastric administration of MDGA significantly lowered the productions of interleukin (IL)-4, IL-5, IL-13, tumor necrosis-α (TNF-α), eotaxin, monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), and immunoglobulin (Ig)E in bronchoalveolar lavage fluid (BALF), plasma, or lung tissues. Histological studies showed that MDGA inhibited OVA-induced inflammatory cell infiltration and mucus production in the respiratory tract. Moreover, MDGA markedly attenuated the OVA-induced activations of nuclear factor kappa B (NF-κB), extracellular-signal-regulated kinases 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK). Together, these results suggest that MDGA effectively inhibits airway inflammation and mucus hypersecretion by downregulating the levels of T helper 2 (Th2) cytokines, chemokines, and adhesion molecules, and inhibiting the activations of NF-κB and MAPKs.


Assuntos
Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Guaiacol/análogos & derivados , Lignanas/uso terapêutico , Pneumonia/tratamento farmacológico , Saururaceae/imunologia , Animais , Movimento Celular/efeitos dos fármacos , Quimiocina CCL2/metabolismo , Citocinas/metabolismo , Feminino , Guaiacol/uso terapêutico , Humanos , Imunoglobulina E/metabolismo , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos BALB C , NF-kappa B/metabolismo , Células Th2/imunologia , Molécula 1 de Adesão de Célula Vascular/metabolismo
2.
Int Immunopharmacol ; 17(2): 471-7, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23928505

RESUMO

Previous studies have shown that sauchinone modulates the expression of inflammatory mediators through mitogen-activated protein kinase (MAPK) pathways in various cell types. However, little information exists about the effect of sauchinone on neutrophils, which play a crucial role in inflammatory process such as acute lung injury (ALI). We found that sauchinone decreased the phosphorylation of p38 MAPK in lipopolysaccharide (LPS)-stimulated murine bone marrow neutrophils, but not ERK1/2 and JNK. Exposure of LPS-stimulated neutrophils to sauchinone or SB203580, a p38 inhibitor, diminished production of tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 compared to neutrophils cultured with LPS. Treatment with sauchinone decreased the level of phosphorylated ribosomal protein S6 (rpS6) in LPS-stimulated neutrophils. Systemic administration of sauchinone to mice led to reduced levels of phosphorylation of p38 and rpS6 in mice lungs given LPS, decreased TNF-α and MIP-2 production in bronchoalveolar lavage fluid, and also diminished the severity of LPS-induced lung injury, as determined by reduced neutrophil accumulation in the lungs, wet/dry weight ratio, and histological analysis. These results suggest that sauchinone diminishes LPS-induced neutrophil activation and ALI.


Assuntos
Lesão Pulmonar Aguda/tratamento farmacológico , Benzopiranos/administração & dosagem , Dioxóis/administração & dosagem , Mediadores da Inflamação/metabolismo , Lignanas/administração & dosagem , Macrófagos/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Saururaceae/imunologia , Lesão Pulmonar Aguda/imunologia , Animais , Benzopiranos/uso terapêutico , Movimento Celular/efeitos dos fármacos , Células Cultivadas , Quimiocina CXCL2/metabolismo , Citocinas/metabolismo , Dioxóis/uso terapêutico , Lipopolissacarídeos/imunologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Macrófagos/imunologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Neutrófilos/imunologia , Fosforilação , Proteína S6 Ribossômica/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
3.
Int Immunopharmacol ; 11(6): 698-705, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21295171

RESUMO

Chronic airway inflammation is a hallmark of asthma, which is an immune-based disease. We evaluated the ability of saucerneol D, a tetrahydrofuran-type sesquilignan isolated from Saururus chinensis, to regulate airway inflammation in an ovalbumin (OVA)-induced airway inflammation model. Furthermore, we determined whether heme oxygenase (HO)-1 was required for the protective activity of saucerneol D. The airways of OVA-sensitized mice exposed to an OVA challenge developed eosinophilia and mucus hypersecretion and exhibited increased cytokine levels. Mice were administered saucerneol D orally at doses of 20 and 40mg/kg once daily on days 26-30. Saucerneol D administered orally significantly inhibited the number of OVA-induced inflammatory cells and the production of immunoglobulin E as well as Th2-type cytokines. Histopathology studies revealed a marked decrease in lung inflammation and goblet cell hyperplasia after saucerneol D treatment. In addition, saucerneol D induced HO-1 and led to a marked decrease in OVA-induced reactive oxygen species and malondialdehyde and an increase in superoxide dismutase and glutathione in lung tissues. These antioxidant effects were correlated with HO-1 induction. In our experiments, saucerneol D treatment reduced airway inflammation and suppressed oxidative stress in an OVA-induced asthma model.


Assuntos
Antiasmáticos/administração & dosagem , Antioxidantes/administração & dosagem , Asma/tratamento farmacológico , Lignanas/administração & dosagem , Pneumonia/tratamento farmacológico , Animais , Antiasmáticos/química , Antioxidantes/química , Asma/imunologia , Células Cultivadas , Citocinas/genética , Citocinas/metabolismo , Modelos Animais de Doenças , Feminino , Heme Oxigenase (Desciclizante)/genética , Heme Oxigenase (Desciclizante)/metabolismo , Humanos , Imunoglobulina E/biossíntese , Imunoglobulina E/sangue , Imunoglobulina E/genética , Lignanas/química , Lignanas/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Pneumonia/induzido quimicamente , Pneumonia/imunologia , Espécies Reativas de Oxigênio/metabolismo , Saururaceae/imunologia , Equilíbrio Th1-Th2/efeitos dos fármacos
4.
Mol Cells ; 20(1): 105-11, 2005 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-16258248

RESUMO

Mannasantin B, a dilignan structurally related to manssantin A, is an inhibitor of NF-kappaB transactivation. In the present study, we found that it inhibited PMA-induced expression of IL-1beta, IL-1beta mRNA, and IL-1beta promoter activity in U937 cells with IC50 values of about 50 nM. It also inhibited NF-IL6- and NF-kappaB-induced activation of IL-1beta, with IC50 values of 78 nM and 1.6 microM, respectively, revealing a potent inhibitory effect on NF-IL6. Electrophoretic mobility shift assays showed that manassantin B had an inhibitory effect on DNA binding by NF-IL6, but not by NF-kappaB. Further analysis revealed that transactivation by NF-IL6 was also inhibited. Our results indicate that manassantin B suppresses expression of IL-1beta in promonocytic cells by inhibiting not only NF-kappaB but also NF-IL6 activity. Furthermore, our observations suggest that manassantin B may be clinically useful as a potent inhibitor of NF-IL6 activity.


Assuntos
Proteína beta Intensificadora de Ligação a CCAAT/metabolismo , Furanos/farmacologia , Saururaceae/metabolismo , Acetato de Tetradecanoilforbol/antagonistas & inibidores , Relação Dose-Resposta a Droga , Ensaio de Desvio de Mobilidade Eletroforética , Humanos , Concentração Inibidora 50 , Interleucina-1/genética , Interleucina-1/metabolismo , Saururaceae/genética , Saururaceae/imunologia , Ativação Transcricional/efeitos dos fármacos , Transfecção , Células U937
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...